|
Pharmacoepidemiology & Pharmacogenomics Resources:
Mention of companies, products or services on this Web site is for reference purposes only
and does not constitute endorsement by NCI or the US Government.
Please read our disclaimer.
|
|
Eudragene
Description
Eudragene is a European collaboration that established a collection of DNA samples as a
resource for studying genes which influence serious or adverse drug reactions (ADRs).
Identifying genes that influence susceptibility to adverse reactions will advance
understanding of the basis of adverse drug reactions and may also lead to the development
of tests that can predict individual susceptibility to adverse reactions.
In the first year they will select for study an initial set of six ADRs that are
important because they cause serious illness in a small number of those exposed to drugs
that are otherwise more effective than any alternative, and that are easily identified
because they produce distinctive conditions that are not related to the disease for which
the drug was prescribed. These include 1) muscle inflammation (myopathy) caused by
cholesterol lowering drugs 2) low white cell blood count (agranulocytosis) caused by (i)
thyroid drugs, (ii) sulphasalazine (used to treat inflammatory bowel conditions and
rheumatoid arthritis) or (iii) clozapine antipsychotics 3) tendinitis and tendon rupture
caused by fluoroquinolone antibiotics 4) long QT syndrome (abnormality of the heart
electrical system) caused by several classes of drug including anti-arrhythmic agents,
antibiotics and antipsychotic agents, 5) liver injury caused by non-steroidal
anti-inflammatory drugs and 6) neuropsychiatric reactions caused by mefloquine
antimalarials.
At least 500 cases of each ADR will be collected, together with an equal number of
healthy volunteers. The coordinating centre will manage the database, and will make
samples freely available to academic and industry-based researchers throughout Europe. The
collection will be extended to include more ADRs after the first 1-2 years, based on
problems of current concern.
|
|